“Our positive results in animals with ongoing disease raise the possibility that oral anti-CD3 antibodies might be an effective immunomodulatory therapy for SLE that could be easily and rapidly ...

as the company targets the billion-dollar lupus market for its CD20-targeting drug Gazyva (obinutuzumab). While the market ...

Lunsumio is a CD20/CD3 T cell-engaging bispecific antibody designed to target CD20 on B cells and CD3 on T cells. Lunsumio is expected to activate the immune system through cytotoxic T cells and have ...